Armata’s AP-SA02 Phage Therapy Shows Genetic Diversity May Improve Activity Against Staph Infections

Key Points

• Armata Pharmaceuticals will present new AP-SA02 data at ISSSI 2026 showing that controlled genetic diversity in its bacteriophage therapy may help it kill certain Staphylococcus aureus strains more effectively.
• AP-SA02 is an investigational multi-phage treatment being developed alongside antibiotics for serious bloodstream infections caused by MSSA or MRSA.
• Armata said its manufacturing process consistently preserves the defined genetic variants across clinical drug-product batches.
• Laboratory findings suggest some genetic variants may be better at infecting and replicating against specific patient-derived S. aureus isolates.
• Armata plans to begin a Phase 3 study of AP-SA02 in complicated S. aureus bloodstream infections in the second half of 2026.

Armata Pharmaceuticals (NYSE: ARMP) plans to present data suggesting that the controlled genetic diversity within AP-SA02 may strengthen its ability to fight certain Staphylococcus aureus infections. The company will present the findings in an oral session at the International Symposium on Staphylococci and Staphylococcal Infections in Banff, Alberta, on September 21, 2026.

AP-SA02 Is a Multi-Phage Therapy for Serious MRSA and MSSA Bloodstream Infections

AP-SA02 is Armata’s investigational, fixed multi-phage cocktail for use as an adjunct to antibiotic therapy in patients with complicated Staphylococcus aureus bacteremia, or bloodstream infection.

The program targets infections caused by both methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). Bacteriophages are viruses that infect bacteria, making phage therapy a potential approach for hard-to-treat bacterial infections, including those involving antibiotic resistance.

AP-SA02 is not approved for commercial use and remains in clinical development.

AP-SA02 Genetic Variants May Improve Killing of Specific Clinical S. aureus Isolates

Armata said genomic analyses showed AP-SA02 has a defined and reproducible profile of genetic variants. In laboratory testing, one component phage was grown on S. aureus isolates collected during the Phase 1b/2a diSArm trial.

Certain variants became enriched depending on the clinical isolate, indicating that some variants may be better able to infect and replicate in particular S. aureus strains. In another experiment, a phage stock lacking those variants showed reduced activity against selected clinical isolates.

The findings suggest that preserving defined genetic diversity may support AP-SA02 activity against a broader set of MSSA and MRSA clinical isolates.

Controlled Manufacturing Maintains AP-SA02 Genetic Diversity Across Drug-Product Batches

Armata said it deliberately uses controlled manufacturing conditions to reproducibly maintain AP-SA02’s defined genetic variants across clinical drug-product lots.

The company considers this genetic diversity an important product attribute. Consistent manufacturing could be particularly important as Armata advances AP-SA02 toward later-stage clinical development, because it aims to ensure that drug-product batches retain the phage characteristics observed in laboratory testing.

The reported findings are preclinical, in vitro observations. They do not independently establish improved clinical outcomes for patients.

Phase 2a diSArm Results Support Planned Phase 3 AP-SA02 Study in S. aureus Bacteremia

The ISSSI 2026 data complement results from Armata’s Phase 2a diSArm study, a multicenter, randomized, double-blind, placebo-controlled trial evaluating intravenous AP-SA02 plus best available antibiotic therapy versus antibiotics alone in adults with complicated S. aureus bacteremia.

According to Armata, 100% of AP-SA02-treated patients who had an evaluable end-of-study assessment achieved a complete clinical response.

The FDA has granted AP-SA02 Qualified Infectious Disease Product, Fast Track, and Breakthrough Therapy designations. Armata plans to initiate a Phase 3 superiority study in complicated S. aureus bacteremia in the second half of 2026.

Why AP-SA02 Manufacturing and Clinical Development Progress Matter for Armata

The presentation highlights an effort to link AP-SA02’s manufacturing process with its intended biological performance against diverse S. aureus strains.

If further clinical studies support the laboratory findings, AP-SA02 could potentially offer an additional treatment approach for complicated MRSA and MSSA bloodstream infections when used with standard antibiotics. The key next step is the planned Phase 3 trial, which will be needed to determine whether AP-SA02’s laboratory activity and Phase 2a results translate into meaningful clinical benefit.